Oncologix Tech

Oncologix Tech EBIT Margin

Delisted·Sep 9, 2026

The EBIT Margin (Operating Margin) of Oncologix Tech (OCLG) as of Oct 28, 2026 is -30.35 %. In the previous year, EBIT Margin (Operating Margin) was -12.76 % — a change of 137.83% (lower).

EBIT Margin

-30.35 %

YoY

137.83%

Last updated:

EBIT Margin (Operating Margin) of Oncologix Tech is 2017 -30.35 % . EBIT Margin (Operating Margin) of Oncologix Tech was 2016 -12.76 % . It decreases by 137.83% lower compared to the previous year.

For Oncologix Tech, the operating (EBIT) margin of -30.4% is up versus -117.5% a few years ago.

The Oncologix Tech EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2004
-2.59 USD
Jan 1, 2005
-0.49 USD
Jan 1, 2006
-5.15 USD
Jan 1, 2013
-1.18 USD
Jan 1, 2014
-15.56 USD
Jan 1, 2015
-10.38 USD
Jan 1, 2016
-12.76 USD
Jan 1, 2017
-30.35 USD
The Oncologix Tech EBIT Margin history
YEAREBIT MarginYoY
-30.35 %+137.83%
-12.76 %+22.90%
-10.38 %-33.25%
-15.56 %+1,223.88%
-1.18 %-77.16%
-5.15 %+956.47%
-0.49 %-81.17%
-2.59 %-2.83%
-2.66 %-39.62%
-4.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oncologix Tech Stock analysis

What does Oncologix Tech do? Oncologix Tech, Inc. generates revenue through the operation and manufacture of medical device products. The company collaborates with manufacturers and stakeholders in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers. It reviews licenses and sublicense agreements with potential licensors and conducts research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. Oncologix Tech, Inc. seeks additional acquisitions of diagnostic and biotechnology opportunities to expand its portfolio. The firm's primary customers include partners, customers, vendors, and manufacturers within the medical device and biotech sectors. It targets opportunities in diagnostic and biotechnology fields through strategic acquisitions and partnerships. Oncologix Tech, Inc. focuses on executing agreements and conducting due diligence to secure new ventures in the biotech industry. Oncologix Tech, Inc. operates as a medical holding company with a focus on medical device products. It engages in reviewing licenses and sublicense agreements and conducts research on potential acquisitions. The company aims to expand its operations by acquiring diagnostic and biotechnology opportunities in the market. Oncologix Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncologix Tech stock

EBIT Margin (Operating Margin) of Oncologix Tech is -30.35 % in 2017.

EBIT Margin (Operating Margin) of Oncologix Tech changed from -12.76 % to -30.35 %, representing a 137.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Oncologix Tech since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Oncologix Tech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Oncologix Tech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Oncologix Tech